Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ArthriXcel is a multi-ingredient nutraceutical product developed by Libytec Pharmaceutical, specifically formulated to support joint health and manage symptoms associated with osteoarthritis and joint degeneration. The formulation typically combines high doses of glucosamine sulfate, chondroitin sulfate, and methylsulfonylmethane (MSM) with hydrolyzed collagen, hyaluronic acid, vitamin C, and manganese. These components work synergistically to provide the essential building blocks for cartilage matrix repair, inhibit degradative enzymes within the joint capsule, and offer anti-inflammatory and antioxidant protection. It is marketed as a dietary supplement to improve joint mobility and reduce pain in patients with degenerative joint diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ArthriXcel.